期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
Mesenchymal stem cells for cartilage regeneration in dogs 被引量:1
1
作者 Akari Sasaki Mitsuru Mizuno +1 位作者 manabu mochizuki Ichiro Sekiya 《World Journal of Stem Cells》 SCIE CAS 2019年第5期254-269,共16页
Articular cartilage damage and osteoarthritis (OA) are common orthopedic diseases in both humans and dogs. Once damaged, the articular cartilage seldom undergoes spontaneous repair because of its avascular, aneural, a... Articular cartilage damage and osteoarthritis (OA) are common orthopedic diseases in both humans and dogs. Once damaged, the articular cartilage seldom undergoes spontaneous repair because of its avascular, aneural, and alymphatic state, and the damage progresses to a chronic and painful situation. Dogs have distinctive characteristics compared to other laboratory animal species in that they share an OA pathology with humans. Dogs can also require treatment for naturally developed OA;therefore, effective treatment methods for OA are desired in veterinary medicine as well as in human medicine. Recently, interest has grown in regenerative medicine that includes the use of mesenchymal stem cells (MSCs). In cartilage repair, MSCs are a promising therapeutic tool due to their self-renewal capacity, ability to differentiate into cartilage, potential for trophic factor production, and capacity for immunomodulation. The MSCs from dogs (canine MSCs;cMSCs) share various characteristics with MSCs from other animal species, but they show some deviations, particularly in their differentiation ability and surface epitope expression. In vivo studies of cMSCs have demonstrated that intraarticular cMSC injection into cartilage lesions results in excellent hyaline cartilage regeneration. In clinical situations, cMSCs have shown great therapeutic effects, including amelioration of pain and lameness in dogs suffering from OA. However, some issues remain, such as a lack of regulations or guidelines and a need for unified methods for the use of cMSCs. This review summarizes what is known about cMSCs, including their in vitro characteristics, their therapeutic effects in cartilage lesion treatment in preclinical in vivo studies, their clinical efficacy for treatment of naturally developed OA in dogs, and the current limitations of cMSC studies. 展开更多
关键词 MESENCHYMAL stem cell Dog CARTILAGE OSTEOARTHRITIS Regenerative MEDICINE VETERINARY MEDICINE
下载PDF
病理性近视患者视乳头周围脱离的特征 被引量:9
2
作者 Noriaki Shimada Kyoko Ohno-Matsui +7 位作者 Takeshi Yoshida Kenjiro Yasuzumi Ariko Kojima Kanako Kobayashi Soh Futagami Takashi Tokoro manabu mochizuki 刘亮(译) 《美国医学会眼科杂志(中文版)》 2006年第4期225-231,共7页
目的:在一组高度近视患者中,评估新近认识的视乳头周围病变。即病理性近视视乳头周围脱离(PD-PM)的患病率和临床特征。 方法:共纳入324位高度近视患者(632只眼)。在这些患者中观察PDPMD的发病率、病变范围、荧光素和吲哚青绿造... 目的:在一组高度近视患者中,评估新近认识的视乳头周围病变。即病理性近视视乳头周围脱离(PD-PM)的患病率和临床特征。 方法:共纳入324位高度近视患者(632只眼)。在这些患者中观察PDPMD的发病率、病变范围、荧光素和吲哚青绿造影检查结果及OCT结果。并对有PDPM的患者进行视野检查(Goldmann动态视野检查法和Humphrey 30-2程序)。结果:632只高度近视眼中有31只眼(4.9%)存在视乳头周围脱离。PDPM病变部位的OCT扫描显示视神经邻近部位视网膜色素上皮层的局限性脱离。PDPM常位于视盘下方。但一些患者的病变几乎环绕整个视盘。邻近PDPM的下方近视弧形斑有陡峭的凹陷。且颞下视网膜静脉在跨过PDPM和凹陷的近视弧形斑时明显弯曲。PDPM眼常被检出存在青光眼性视野缺损(71.0%)。 结论:本研究表明PDPM在高度近视眼中并非罕见。虽然其发病机制和病理学意义尚需进一步分类。高度近视PDPM的出现提示可能存在视野缺损。 展开更多
关键词 视乳头周围脱离 近视患者 病理性近视 视网膜色素上皮层 高度近视眼 视野检查法 吲哚青绿造影 周围病变
下载PDF
Total cystectomy of 10 dogs with transitional cell carcinoma of urinary bladder involving trigonal area-retrospective case study
3
作者 Kohei Saeki Atsushi Fujita +2 位作者 Takayuki Nakagawa manabu mochizuki Ryohei Nishimura 《畜牧与兽医》 北大核心 2012年第S2期32-32,共1页
Transitional cell carcinoma(TCC)is the most common tumor of urinary bladder(UB)in dogs.TCC usually has high invasiveness and frequent involvement of trigone region,and therefore most TCC in dogs are judged as unresect... Transitional cell carcinoma(TCC)is the most common tumor of urinary bladder(UB)in dogs.TCC usually has high invasiveness and frequent involvement of trigone region,and therefore most TCC in dogs are judged as unresectable when diagnosed.Moreover,tumor involvement of trigone region and urethra could cause partial or complete urinary tract obstruction.As TCCs are clinically highly malignant,median survival time of the patients with TCCs at any TMN stage has been reported to be less than 1 year regardless of the type of surgical intervention and chemotherapeutic regimen in most previously studies. 展开更多
关键词 BLADDER CYSTECTOMY URINARY transitional OBSTRUCTION regardless retrospective involvement judged REGIMEN
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部